Repros Provides Update on EU Submission of Enclomiphene for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
  • EU submission on track with anticipated registration decision expected Fall 2017
    • UK designated as rapporteur and France as co-rapporteur for the centralized review of the enclomiphene marketing application
  • 3 month interim assessment of testosterone levels in obese men participating in Phase 2 diet and exercise study show statistically significant increases in testosterone in the active arms versus the placebo arm

THE WOODLANDS, Texas, June 01, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX ) today announced that it remains on track for submission of a European centralized marketing authorization application (MAA) for enclomiphene for the treatment of secondary hypogonadism. To that end, the European Medicines Agency (EMA) has assigned France and the UK as rapporteurs for the application review. The Company expects to submit the application in Fall 2016.  As part of the review process, the Company is scheduled to meet with British and French medical reviewers in June 2016. 

Secondary hypogonadism is recognized in Europe. The epidemiology of the disorder, based on published evidence from the European Male Aging Study (EMAS), has been well reported and the Company believes that it is well understood amongst key European thought leaders.

US Development of Enclomiphene in the Treatment of Secondary Hypogonadism

The US FDA currently approves testosterone therapies for the treatment of “Classical Hypogonadism”. The FDA defines this disorder as essentially a condition in which the testes are no longer functional (other than for old age) and/or the pituitary is defective. As required by the FDA, in order for any drug to be approved for treating men with secondary hypogonadism, a clinical benefit other than increasing testosterone must be determined in well controlled clinical studies. To that end, the Company is conducting the ongoing Phase 2 diet and exercise study evaluating numerous endpoints which could be deemed as clinically beneficial.  There are two active arms dosing men with 12.5 and 25 mg of enclomiphene and one placebo group.

During the first six month phase of the study, men are provided a commercially available prepared diet along with enrollment in a health club with a personal trainer. Subjects are asked to attend the health club at least three times per week. At the end of the six month period the subjects will be assessed for changes in a variety of biochemical markers as well as anatomical markers such as waist circumference, lean body mass and BMI. Quality of life will also be assessed. The six month data should be available in Fall 2016.

During the second six month phase, men will continue treatment with enclomiphene or placebo but will no longer be provided the commercial diet. Exercise with the assigned trainer will continue during this period. A second assessment for changes previously monitored will be made and reported.

In the last three months of the study, the subjects will no longer receive treatment but will stay enrolled in the health club, though, without a trainer.

After three months of treatment, all groups lost weight.  However, the weight loss exhibited in the placebo group did not yield increased levels of testosterone.  The placebo group had an average testosterone level of 221 ng/dL at baseline. After three months of diet and exercise the average testosterone level dropped to 214 ng/dL. For the active arms, the mean baseline testosterone increased from 212 ng/dL to 399 ng/dL. The difference between the active and placebo group was highly significant, p<0.0001. Metabolic function was not assessed at the three month time point.

The Company plans to report metabolic and anatomical effects, including change in lean body mass, after the six month assessment.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should” or similar expressions. These statements are based on assumptions that the Company has made in light of the Company’s experience in the industry, as well as the Company’s perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to the possibility of obtaining marketing authorization from the EMA, the timeframe for such process, the potential marketing opportunities that could follow such authorization, the timing and nature of the results of clinical studies, and possible future interactions with the FDA. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including risks that the EMA may not ultimately grant the marketing authorization, on the expected timeline or at all, the risk that the marketing authorization, if granted, may have significant limitations on use, that even if the marketing authorization is ultimately granted, the Company may not be able to successfully commercialize the product candidate, that additional clinical studies may not be successfully undertaken or completed, that the FDA may not ultimately approve the product candidate, the risk that any marketing approvals, if granted, may have significant limitations on use, that even if an NDA is approved, the Company may not be able to successfully commercialize the product candidate, risks relating to the Company’s ability to protect its intellectual property rights and such other risks as are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company’s website at http://www.reprosrx.com .

CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 thoffmann@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 93

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 75

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 89

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
PostalAnnex Adds Roseville Store as Owners Reach Three

Updated Category News Views 97

A third storefront from the same operators says more than a ribbon-cutting ever will. Aarondeep Hira and Manraj Sangha have opened a PostalAnnex in Roseville, California, their third Sacramento-area location after earlier operations in Sacramento and Antelope. For a franchise system, repeat ownership is the part worth noticing. It is not a guarantee of booming sales, and...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 128

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 118

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading

Top 5 Most Recently Viewed Articles

Transparency in Securities Disclosure: Learning Technologies' Interest

Updated Category News Views 111

Key Information About Securities Disclosure In the evolving landscape of financial regulations, transparency stands as a foundational requirement for public companies. One of the pivotal rules governing such disclosures is laid out in Rule 8.3 of the Takeover Code. This rule mandates that entities or individuals with interests in relevant securities of 1% or more must...

Continue Reading
Chart Industries Inc. Reports Impressive Q2 Performance

Updated Category News Views 115

Exceptional Financial Growth in Q2 Chart Industries, Inc. (NASDAQ: GTLS) shared its financial results for the second quarter. The company witnessed notable growth compared to the previous year's quarter, marking a significant trajectory in its market position. Quarterly Highlights In the second quarter, Chart Industries recorded orders totaling $1.50 billion, representing...

Continue Reading
Marine Lubricants Market Growth Forecast: USD 7.8 Billion

Updated Category News Views 70

Overview of the Marine Lubricants Market The marine lubricants market is steadily growing, with forecasts estimating its value will reach an impressive USD 7.8 billion by 2032. This growth is driven by a compound annual growth rate (CAGR) of 2.07% during the period from 2024 to 2032. Key Drivers Behind Market Growth One of the main factors fueling this market's growth is...

Continue Reading
Celebrating Diversity in Arbitration: CCA’s New Class Announced

Updated Category News Views 185

Celebrating Diversity with New CCA Associates Class The College of Commercial Arbitrators (CCA) is thrilled to introduce the new class of Associates for the 2025–2027 mentorship program. This initiative, started in 2022, highlights the CCA's commitment to nurturing emerging talent in the field of commercial arbitration, particularly from underrepresented backgrounds. By...

Continue Reading
Big Bronze Unveils Final K9 Statue to Honor Veterans

Updated Category News Views 211

Big Bronze Completes Veteran's Memorial with Final K9 Statue Big Bronze, renowned for its exquisite bronze sculptures, is thrilled to share the news of completing an important project at Veterans Memorial Park. This milestone marks the addition of the fourth and final statue in a series designed to honor the sacrifices of U.S. veterans. A Tribute to Valor and Sacrifice...

Continue Reading